Grindeks Kalceks Danmark ApS - CVR: 44109379

2023, DKK

11.07.2024

Bruttoresultat

-82.514

Primær drift

-333'

Årets resultat

-333'

Aktiver

40.179

Kortfristede aktiver

40.179

Egenkapital

-293'

Afkastningsgrad

-830 %

Soliditetsgrad

-730 %

Likviditetsgrad

12 %

Resultat

11.07.2024

Årsrapport	2023 11.07.2024
Nettoomsætning
Bruttoresultat	-82.514
Resultat af primær drift	-333.403
Indtægter af kapitalandele (tilknyttede og associerede)	0
Finansielle indtægter	180
Finansieringsomkostninger	-217
Andre finansielle omkostninger	0
Resultat før skat	0
Resultat	-333.440
Forslag til udbytte	0

Aktiver

11.07.2024

Årsrapport	2023 11.07.2024
Kortfristede varebeholdninger	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	0
Likvider	40.179
Kortfristede aktiver	40.179
Immaterielle aktiver og goodwill	0
Finansielle anlægsaktiver	0
Materielle aktiver	0
Langfristede aktiver	0
Aktiver	40.179

Aktiver

11.07.2024

Passiver

11.07.2024

Årsrapport	2023 11.07.2024
Forslag til udbytte	0
Egenkapital	-293.440
Hensatte forpligtelser	0
Langfristet gæld til banker	0
Leverandører af varer og tjenesteydelser	0
Kortfristede forpligtelser	333.619
Gældsforpligtelser	333.619
Forpligtelser	333.619
Passiver	40.179

Passiver

11.07.2024

Nøgletal

11.07.2024

Årsrapport	2023 11.07.2024
Afkastningsgrad	-829,8 %
Dækningsgrad	Na.
Resultatgrad	Na.
Varelagerets omsætningshastighed	Na.
Egenkapitals-forretning	113,6 %
Payout-ratio	Na.
Gældsdæknings-nøgletal	-153.641,9 %
Soliditestgrad	-730,3 %
Likviditetsgrad	12,0 %

Resultat

11.07.2024

Gæld

11.07.2024

Årsrapport

11.07.2024

Nyeste:01.06.2023- 31.12.2023(offentliggjort: 11.07.2024)

Information om virksomhedens regnskabsklasse:The annual report of Grindeks Kalceks Danmark ApS for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

11.07.2024

Dato for ledelsens godkendelse af årsrapporten:2024-07-09

Oplysning om usædvanlige forhold:In the financial year 2023, the company has realized a significant loss. A minor profit is expected for the financial year 2024. The loss in 2023 is due to the fixed cost related to the start up phase of the activity in the company. The company has received a letter of support from the parent company in order to support Grindeks Kalceks Danmark ApS' obligations and liabilities in full year of 2024 so the Company will have the necessary financing to meet its liabilitites and continue its operations in Denmark. The support letter covers 2024. Based on the support letter, it is the management’s assessment that the Company is going concern and has sufficient capital preparedness to continue operations in 2024.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Executive Board has discussed and approved the annual report of Grindeks Kalceks Danmark ApS for the financial year as of the establishment of the Company 1 June - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The company's purpose is the distribution and wholesale of pharmaceuticals and active ingredients (APIs) for the manufacture of pharmaceuticals, including but not limited to participation in public tenders and sales to hospitals, market research and retail sales of pharmaceuticals through pharmacies